{"news_desk": "Business", "print_page": "1", "subsection_name": null, "section_name": "Business Day", "byline": {"original": "By KATIE THOMAS", "person": [{"firstname": "Katie", "rank": 1, "lastname": "THOMAS", "organization": "", "role": "reported"}]}, "abstract": null, "type_of_material": "News", "word_count": "1240", "keywords": [{"rank": "3", "value": "Prices (Fares, Fees and Rates)", "is_major": "N", "name": "subject"}, {"rank": "4", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "name": "subject"}, {"rank": "5", "value": "Generic Brands and Products", "is_major": "N", "name": "subject"}, {"rank": "6", "value": "Medical Devices", "is_major": "N", "name": "subject"}, {"rank": "7", "value": "Epinephrine (Drug)", "is_major": "N", "name": "subject"}, {"rank": "8", "value": "Mylan Inc", "is_major": "N", "name": "organizations"}, {"rank": "9", "value": "Impax Laboratories Inc", "is_major": "N", "name": "organizations"}], "lead_paragraph": "Adrenaclick, a cheaper alternative, has benefited from furor over EpiPen pricing. But its maker is struggling to meet demand, and a generic EpiPen is near.", "pub_date": "2016-11-01T09:00:19Z", "document_type": "article", "source": "The New York Times", "snippet": "Adrenaclick, a cheaper alternative, has benefited from furor over EpiPen pricing. But its maker is struggling to meet demand, and a generic EpiPen is near....", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wide": "images/2016/11/05/business/05ADRENACLICKweb1/05ADRENACLICKweb1-thumbWide.jpg", "wideheight": "126"}, "type": "image", "width": 190, "url": "images/2016/11/05/business/05ADRENACLICKweb1/05ADRENACLICKweb1-thumbWide.jpg"}, {"height": 899, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "899", "xlarge": "images/2016/11/05/business/05ADRENACLICKweb1/05ADRENACLICKweb1-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2016/11/05/business/05ADRENACLICKweb1/05ADRENACLICKweb1-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/11/05/business/05ADRENACLICKweb1/05ADRENACLICKweb1-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "url": "images/2016/11/05/business/05ADRENACLICKweb1/05ADRENACLICKweb1-thumbStandard.jpg"}], "web_url": "http://www.nytimes.com/2016/11/02/business/also-ran-to-epipen-reaches-for-a-closing-window-of-opportunity.html", "slideshow_credits": null, "blog": [], "_id": "581859ab7c459f606398cde8", "headline": {"main": "Why the Lone EpiPen Competitor Hasn\u2019t Taken Off", "print_headline": "A Promising Rival to EpiPen Fails to Gain Traction"}}